DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 Jan 2024
Historique:
received: 23 12 2022
accepted: 27 10 2023
medline: 20 1 2024
pubmed: 20 1 2024
entrez: 19 1 2024
Statut: epublish

Résumé

Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined transcriptomic data derived from peripheral blood mononuclear cells of HF patients, both with and without CHIP, and cardiac tissue. We demonstrate that inactivation of DNMT3A in macrophages intensifies interactions with cardiac fibroblasts and increases cardiac fibrosis. DNMT3A inactivation amplifies the release of heparin-binding epidermal growth factor-like growth factor, thereby facilitating activation of cardiac fibroblasts. These findings identify a potential pathway of DNMT3A CHIP-driver mutations to the initiation and progression of HF and may also provide a compelling basis for the development of innovative anti-fibrotic strategies.

Identifiants

pubmed: 38242884
doi: 10.1038/s41467-023-43003-w
pii: 10.1038/s41467-023-43003-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

606

Subventions

Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SFB 1366
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SFB 1531

Informations de copyright

© 2023. The Author(s).

Références

Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).
pubmed: 25931582 pmcid: 4624443 doi: 10.1182/blood-2015-03-631747
Evans, M. A. & Walsh, K. Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiol. Rev. 103, 649–716 (2023).
pubmed: 36049115 doi: 10.1152/physrev.00004.2022
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
pubmed: 25426837 pmcid: 4306669 doi: 10.1056/NEJMoa1408617
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
pubmed: 28636844 pmcid: 6717509 doi: 10.1056/NEJMoa1701719
Heimlich, J. B. & Bick, A. G. Somatic mutations in cardiovascular disease. Circ. Res. 130, 149–161 (2022).
pubmed: 34995138 pmcid: 8827644 doi: 10.1161/CIRCRESAHA.121.319809
Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335–342 (2022).
pubmed: 35650444 pmcid: 9177423 doi: 10.1038/s41586-022-04785-z
Yu, B. et al. Supplemental association of clonal hematopoiesis with incident heart failure. J. Am. Coll. Cardiol. 78, 42–52 (2021).
pubmed: 34210413 pmcid: 8313294 doi: 10.1016/j.jacc.2021.04.085
Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 25–33 (2019).
pubmed: 30566180 doi: 10.1001/jamacardio.2018.3965
Assmus, B. et al. Clonal haematopoiesis in chronic ischaemic heart failure: Prognostic role of clone size for DNMT3A-and TET2-driver gene mutations. Eur. Heart J. 42, 257–265 (2021).
pubmed: 33241418 doi: 10.1093/eurheartj/ehaa845
Mas-Peiro, S. et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur. Heart J. 41, 933–939 (2020).
pubmed: 31504400 doi: 10.1093/eurheartj/ehz591
Kiefer, K. C. et al. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality. ESC Hear. Fail. 8, 1873–1884 (2021).
doi: 10.1002/ehf2.13297
Pascual-Figal, D. A. et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J. Am. Coll. Cardiol. 77, 1747–1759 (2021).
pubmed: 33832602 doi: 10.1016/j.jacc.2021.02.028
Sano, S. et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71, 875–886 (2018).
pubmed: 29471939 pmcid: 5828038 doi: 10.1016/j.jacc.2017.12.037
Sano, S. et al. CRISPR-mediated gene editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and cardiovascular disease. Circ. Res. 123, 335–341 (2018).
pubmed: 29728415 pmcid: 6054544 doi: 10.1161/CIRCRESAHA.118.313225
Abplanalp, W. T. et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ. Res. 128, 216–228 (2021).
pubmed: 33155517 doi: 10.1161/CIRCRESAHA.120.317104
Zeiher, A. M. et al. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 5, 1170–1175 (2020).
pubmed: 32639511 doi: 10.1001/jamacardio.2020.2468
Lavine, K. J. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc. Natl Acad. Sci. USA 111, 16029–16034 (2014).
pubmed: 25349429 pmcid: 4234568 doi: 10.1073/pnas.1406508111
Li, W. et al. Heart-resident CCR2+ macrophages promote neutrophil extravasation through TLR9/MyD88/CXCL5 signaling. JCI Insight 1 (2016).
Bajpai, G. et al. The human heart contains distinct macrophage subsets with divergent origins and functions. Nat. Med. 24, 1234–1245 (2018).
pubmed: 29892064 pmcid: 6082687 doi: 10.1038/s41591-018-0059-x
Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes. Nat. Protoc. 15, 1484–1506 (2020).
pubmed: 32103204 doi: 10.1038/s41596-020-0292-x
Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1–20 (2021).
doi: 10.1038/s41467-021-21246-9
Nicin, L. et al. A human cell atlas of the pressure-induced hypertrophic heart. Nat. Cardiovasc. Res. 1, 174–185 (2022).
doi: 10.1038/s44161-022-00019-7
Litviňuková, M. et al. Cells of the adult human heart. Nature 588, 466–472 (2020).
pubmed: 32971526 pmcid: 7681775 doi: 10.1038/s41586-020-2797-4
Bajpai, G. et al. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ. Res. 124, 263–278 (2019).
pubmed: 30582448 pmcid: 6626616 doi: 10.1161/CIRCRESAHA.118.314028
Gaulin, C., Kelemen, K. & Arana Yi, C. Molecular pathways in clonal hematopoiesis: from the acquisition of somatic mutations to transformation into hematologic neoplasm. Life 12 (2022).
Gibb, A. A., Lazaropoulos, M. P. & Elrod, J. W. Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ. Res. 127, 427–447 (2020).
pubmed: 32673537 pmcid: 7982967 doi: 10.1161/CIRCRESAHA.120.316958
Fu, X., Liu, Q., Li, C., Li, Y. & Wang, L. Cardiac fibrosis and cardiac fibroblast lineage-tracing: recent advances. Front. Physiol. 11 (2020).
Ma, Z. G., Yuan, Y. P., Wu, H. M., Zhang, X. & Tang, Q. Z. Cardiac fibrosis: new insights into the pathogenesis. Int. J. Biol. Sci. 14, 1645–1657 (2018).
pubmed: 30416379 pmcid: 6216032 doi: 10.7150/ijbs.28103
Saadat, S. et al. Pivotal role of TGF-β/Smad signaling in cardiac fibrosis: non-coding RNAs as effectual players. Front. Cardiovasc. Med. 7, 1–18 (2021).
doi: 10.3389/fcvm.2020.588347
Tallquist, M. D. & Molkentin, J. D. Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 14, 484–491 (2017).
pubmed: 28436487 pmcid: 6329009 doi: 10.1038/nrcardio.2017.57
Herum, K. M., Choppe, J., Kumar, A., Engler, A. J. & McCulloch, A. D. Mechanical regulation of cardiac fibroblast profibrotic phenotypes. Mol. Biol. Cell 28, 1871–1882 (2017).
pubmed: 28468977 pmcid: 5541838 doi: 10.1091/mbc.e17-01-0014
Wagner, J. U. G. et al. Dissection of heterocellular cross-talk in vascularized cardiac tissue mimetics. J. Mol. Cell. Cardiol. 138, 269–282 (2020).
pubmed: 31866374 doi: 10.1016/j.yjmcc.2019.12.005
Hussain, S. et al. Hyperglycemia induces myocardial dysfunction via epigenetic regulation of JunD. Circ. Res. 127, 1261–1273 (2020).
pubmed: 32815777 doi: 10.1161/CIRCRESAHA.120.317132
Scheller, M. et al. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nat. Cancer 2, 527–544 (2021).
pubmed: 35122024 doi: 10.1038/s43018-021-00213-9
Meyer, I. S. et al. The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction. EMBO Mol. Med. 9, 1279–1293 (2017).
pubmed: 28774883 pmcid: 5582413 doi: 10.15252/emmm.201707565
Kim, P. K. et al. Myocardial T1 and T2 mapping: techniques and clinical applications. Korean J. Radiol. 18, 113–131 (2017).
pubmed: 28096723 pmcid: 5240500 doi: 10.3348/kjr.2017.18.1.113
Puntmann, V. O., Peker, E., Chandrashekhar, Y. & Nagel, E. T1 Mapping in characterizing myocardial disease: a comprehensive review. Circ. Res. 119, 277–299 (2016).
pubmed: 27390332 doi: 10.1161/CIRCRESAHA.116.307974
Puntmann, V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 1265–1273 (2020).
pubmed: 32730619 pmcid: 7385689 doi: 10.1001/jamacardio.2020.3557
Wang, J. et al. Native T1 and T2 mapping by cardiovascular magnetic resonance imaging in pressure overloaded left and right heart diseases. J. Thorac. Dis. 10, 2968–2975 (2018).
pubmed: 29997963 pmcid: 6006079 doi: 10.21037/jtd.2018.04.141
Makki, N., Thiel, K. W. & Miller, F. J. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int. J. Mol. Sci. 14, 20597–20613 (2013).
pubmed: 24132149 pmcid: 3821633 doi: 10.3390/ijms141020597
Purdom, S. & Chen, Q. M. Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts. J. Pharmacol. Exp. Ther. 312, 1179–1186 (2005).
pubmed: 15574683 doi: 10.1124/jpet.104.077057
Seals, D. F. & Courtneidge, S. A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17, 7–30 (2003).
pubmed: 12514095 doi: 10.1101/gad.1039703
Fischer, C. et al. Long-term functional and structural preservation of precision-cut human myocardium under continuous electromechanical stimulation in vitro. Nat. Commun. 10, 1–12 (2019).
Wang, L. et al. Inhibition of EGF receptor blocks the development and progression of peritoneal fibrosis. J. Am. Soc. Nephrol. 27, 2631–2644 (2016).
pubmed: 26677863 doi: 10.1681/ASN.2015030299
Fu, X. et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J. Clin. Invest. 128, 2127–2143 (2018).
pubmed: 29664017 pmcid: 5957472 doi: 10.1172/JCI98215
Han, M. & Zhou, B. Role of cardiac fibroblasts in cardiac injury and repair. Curr. Cardiol. Rep. 24, 295–304 (2022).
pubmed: 35028821 doi: 10.1007/s11886-022-01647-y
Van Linthout, S., Miteva, K. & Tschöpe, C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc. Res. 102, 258–269 (2014).
pubmed: 24728497 doi: 10.1093/cvr/cvu062
Lian, H. et al. Heparin-binding EGF-like growth factor induces heart interstitial fibrosis via an Akt/mTor/p70s6k pathway. PLoS ONE 7 (2012).
Ushikoshi, H. et al. Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes. Lab. Investig. 85, 862–873 (2005).
pubmed: 15856048 doi: 10.1038/labinvest.3700282
Fujino, T. et al. Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc. Res. 38, 365–374 (1998).
pubmed: 9709397 doi: 10.1016/S0008-6363(98)00010-8
Tanaka, N. et al. A role of heparin-binding epidermal growth factor-like growth factor in cardiac remodeling after myocardial infarction. Biochem. Biophys. Res. Commun. 297, 375–381 (2002).
pubmed: 12237129 doi: 10.1016/S0006-291X(02)02197-6
Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat. Med. 8, 35–40 (2002).
pubmed: 11786904 doi: 10.1038/nm0102-35
Peng, K. et al. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II. J. Cell. Mol. Med. 20, 482–494 (2016).
pubmed: 26762600 pmcid: 4759478 doi: 10.1111/jcmm.12763
Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M. & Gouda, A. M. Globally approved egfr inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules 26 (2021).
Yoshioka, J. et al. Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc. Natl Acad. Sci. USA 102, 10622–10627 (2005).
pubmed: 16020536 pmcid: 1180761 doi: 10.1073/pnas.0501198102
Shoykhet, M. et al. EGFR inhibition leads to enhanced desmosome assembly and cardiomyocyte cohesion via ROCK activation. JCI Insight 8 (2023).
Kühn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427–1429 (1995).
pubmed: 7660125 doi: 10.1126/science.7660125
Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
pubmed: 17251932 doi: 10.1038/nature05541
Weinreuter, M. et al. Ca M Kinase II mediates maladaptive post-infarct remodeling and pro-inflammatory chemoattractant signaling but not acute myocardial ischemia/reperfusion injury. EMBO Mol. Med. 6, 1231–1245 (2014).
pubmed: 25193973 pmcid: 4287929 doi: 10.15252/emmm.201403848
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr. Protoc. 1 (2021).

Auteurs

Mariana Shumliakivska (M)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.

Guillermo Luxán (G)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.

Inga Hemmerling (I)

Department of Internal Medicine III, University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120, Heidelberg, Germany.

Marina Scheller (M)

Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

Xue Li (X)

Department of Internal Medicine III, University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120, Heidelberg, Germany.

Carsten Müller-Tidow (C)

Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

Bianca Schuhmacher (B)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Zhengwu Sun (Z)

Walter-Brendel-Centre of Experimental Medicine, Hospital of the Ludwig-Maximilians-University Munich, Marchioninistraße 68, 81377, München, Germany.

Andreas Dendorfer (A)

Walter-Brendel-Centre of Experimental Medicine, Hospital of the Ludwig-Maximilians-University Munich, Marchioninistraße 68, 81377, München, Germany.

Alisa Debes (A)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Simone-Franziska Glaser (SF)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.

Marion Muhly-Reinholz (M)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Klara Kirschbaum (K)

Department of Medicine, Cardiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Jedrzej Hoffmann (J)

German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Institute of Experimental and Translational Cardiovascular Imaging, Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Eike Nagel (E)

German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Institute of Experimental and Translational Cardiovascular Imaging, Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Valentina O Puntmann (VO)

German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Institute of Experimental and Translational Cardiovascular Imaging, Centre for Cardiovascular Imaging, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Sebastian Cremer (S)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.
Department of Medicine, Cardiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Florian Leuschner (F)

Department of Internal Medicine III, University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120, Heidelberg, Germany.

Wesley Tyler Abplanalp (WT)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.

David John (D)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.

Andreas M Zeiher (AM)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany.

Stefanie Dimmeler (S)

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. dimmeler@em.uni-frankfurt.de.
German Center of Cardiovascular Research (DZHK), Partner Site Rhine/Main, 60439, Frankfurt am Main, Germany. dimmeler@em.uni-frankfurt.de.
Cardiopulmonary Institute (CPI), 60590, Frankfurt, Germany. dimmeler@em.uni-frankfurt.de.

Classifications MeSH